The Case Against Approving a Flawed Multicancer Screening Test

October 6, 2026 - 12:29

Telling more people they have cancer is not progress; progress is having fewer people die from cancer. That argument sits at the center of a growing debate over whether regulators should clear a blood based screening tool designed to detect multiple cancers at once.

The test, developed by Grail, promises to find signs of cancer before symptoms appear. On its surface, that sounds like a breakthrough. Catch cancer early, treat it sooner, save lives. But the reality of screening is far messier than the pitch suggests.

Screening tests do not simply find dangerous cancers. They also find slow growing tumors that would never have caused harm. That leads to overdiagnosis, where people receive aggressive treatments for conditions that posed little threat. They endure surgery, radiation, and anxiety for a disease that might never have affected them.

There is also the problem of false reassurance. A negative result does not guarantee a person is cancer free. It may simply mean the test missed something. That can delay real diagnosis and real treatment.

Supporters point to early detection as an obvious good. Critics counter that a test must prove it reduces deaths, not just that it finds more tumors. So far, the evidence for this multicancer screening approach has not shown that it saves lives. Without that proof, approval would offer hope that the data does not support.